Press Releases

Date Title View
Toggle SummaryJanuary 8, 2019 GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2018
CARLSBAD, Calif. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2018 .
View HTML
Toggle SummaryDecember 26, 2018 GenMark Diagnostics Receives FDA 510(k) Market Clearance for its ePlex Blood Culture Identification Fungal Pathogen Panel
Two of Three ePlex Blood Culture Identification Panels Now Cleared for Marketing in the U.S. CARLSBAD, Calif. , Dec. 26, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has
View HTML
Toggle SummaryDecember 20, 2018 GenMark Diagnostics Receives FDA 510(k) Market Clearance for its ePlex Blood Culture Identification Gram-Positive Panel
CARLSBAD, Calif. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has received FDA 510(k) market clearance from the U.S.
View HTML
Toggle SummaryDecember 19, 2018 GenMark Diagnostics to Present at the J.P. Morgan Healthcare Conference
CARLSBAD, Calif. , Dec. 19, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the Company plans to participate in the J.P. Morgan Healthcare Conference in San Francisco, CA.
View HTML
Toggle SummaryNovember 7, 2018 GenMark Diagnostics to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the company plans to participate in two upcoming investor conferences.
View HTML
Toggle SummaryOctober 29, 2018 GenMark Diagnostics Reports Third Quarter 2018 Results
CARLSBAD, Calif. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2018 .
View HTML
Toggle SummaryOctober 15, 2018 GenMark Diagnostics Schedules Third Quarter Financial Results Conference Call for October 29, 2018
CARLSBAD, Calif. , Oct. 15, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Monday, October 29, 2018. Management will hold a conference call to review the Company's financial
View HTML
Toggle SummaryOctober 2, 2018 GenMark Diagnostics Announces FDA Submission of its ePlex Blood Culture Identification Gram-Negative and ePlex Blood Culture Identification Fungal Pathogen Panels
Submissions Now Complete for All Three ePlex Molecular Multiplex Panels Designed for the Diagnosis and Management of Bloodstream Infections That Can Lead to Sepsis CARLSBAD, Calif. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated,
View HTML
Toggle SummaryJuly 30, 2018 GenMark Diagnostics Reports Second Quarter 2018 Results
CARLSBAD, Calif. , July 30, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2018 .
View HTML
Toggle SummaryJuly 25, 2018 GenMark Diagnostics to Present at the Canaccord Genuity 38th Annual Growth Conference
CARLSBAD, Calif. , July 25, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany , will participate in the Canaccord Genuity 38th
View HTML